香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公告所提述的本公司證券的邀請或要約。 GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業（開曼）控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6998） (1)於2025年12月22日舉行之股東特別大會的表決結果； (2)授予清洗豁免及同意特別交易； 及 (3)增加本公司法定股本 茲提述嘉和生物藥業（開曼）控股有限公司（「本公司」）日期為2025年12月5日之 通函（「該通函」）及股東特別大會通告（「股東特別大會通告」），內容有關（其中 包括）建議合併、新上市申請、清洗豁免、股東人員留任計劃、建議更改公司名 稱、建議增加本公司法定股本及建議採納一次性購股權計劃（統稱「該等交易」）。 除文義另有所指外，本公告所用詞彙與該通函所界定者具有相同涵義。 股東特別大會投票表決結果 在本公司於2025年12月22日（星期一）舉行並由 ...

Core Viewpoint - The inclusion of Lairosilib (GB491) in the National Medical Insurance Drug List is expected to enhance patient accessibility and accelerate commercialization, thereby boosting innovative returns for the company [1]. Group 1: Drug Inclusion - Lairosilib (GB491) has been included in the National Medical Insurance Drug List published by the National Healthcare Security Administration, effective from January 1, 2026 [1]. - This marks the first time Lairosilib (GB491) has been included in the national medical insurance drug list [1]. Group 2: Drug Description and Indications - Lairosilib (GB491) is a novel, highly selective oral CDK4/6 inhibitor, indicated for adult patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer [1]. - It is used in combination with aromatase inhibitors as initial endocrine therapy and with Fulvestrant for patients with disease progression after prior endocrine therapy [1]. Group 3: Impact on Patients and Market - The inclusion in the insurance list is expected to significantly improve drug accessibility for patients and reduce their financial burden [1]. - This development is anticipated to accelerate the commercialization process and market penetration of Lairosilib (GB491) [1].

Core Viewpoint - The inclusion of Lairosilib (GB491) in the National Medical Insurance Drug List is expected to enhance patient accessibility and accelerate commercialization, thereby boosting innovative returns [1] Group 1: Drug Inclusion - Lairosilib (GB491) has been included in the National Medical Insurance Drug List published by the National Healthcare Security Administration on December 7, 2025 [1] - This marks the first time Lairosilib (GB491) has been included in the national medical insurance drug list [1] - The new drug list will take effect on January 1, 2026 [1] Group 2: Drug Profile - Lairosilib (GB491) is a novel, highly selective oral CDK4/6 inhibitor indicated for adult patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer [1] - It is used in combination with aromatase inhibitors as initial endocrine therapy and with Fulvestrant for patients with disease progression after prior endocrine therapy [1] Group 3: Market Impact - The company believes that the inclusion of Lairosilib (GB491) in the insurance list will significantly improve patient access to the drug and reduce their financial burden [1] - This development is expected to accelerate the commercialization process and market penetration of Lairosilib (GB491) [1] - The move is anticipated to further enhance innovative returns for the company [1]

Core Viewpoint - Jiahe Biotech-B (06998.HK) announced that its drug Lairosili (GB491) has been included in the National Medical Insurance Drug List (2025) released by the National Healthcare Security Administration on December 7, 2025, marking its first inclusion in the national medical insurance drug list [1] Group 1 - Lairosili (GB491) is a novel, highly selective oral CDK4/6 inhibitor indicated for adult patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer [1] - The new National Medical Insurance Drug List will take effect on January 1, 2026 [1] - The inclusion of Lairosili (GB491) in the medical insurance list is expected to significantly enhance patient accessibility to the drug and reduce their financial burden [1] Group 2 - The company believes that the inclusion in the insurance list will accelerate the commercialization process and market penetration of Lairosili (GB491), further boosting innovation returns [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告由嘉和生物藥業（開曼）控股有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，以知會本公司股東及潛在投資者有關本集團最新業務更新。 （股份代號：6998） 來羅西利(GB491)納入國家醫保藥品目錄 本公司董事會（「董事會」）宣佈，來羅西利(GB491)已納入由國家醫療保障局於 2025年12月7日發佈的《國家基本醫療保險、生育保險和工傷保險藥品目錄（2025 年）》（「國家醫保藥品目錄」）。此乃來羅西利(GB491)首次被納入國家醫保藥品目 錄。新版國家醫保藥品目錄將於2026年1月1日起生效。 GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業（開曼）控股有限公司 （於開曼群島註冊成立的有限公司） 自願公告 嘉和生物藥業（開曼）控股有限公司 執行董事及首席財務官 翁承毅先生 香港，2025年12月8日 於本公告日期，董事會由六(6)名董事組成，即執行董事 ...

Core Viewpoint - The reverse acquisition of Jiahe Biotechnology-B by Yiteng Pharmaceutical marks a significant milestone as the first reverse merger of an unprofitable biotech company in the Hong Kong market, with the merger expected to be completed by December 30 [2][3]. Group 1: Merger Details - Yiteng Pharmaceutical will acquire Jiahe Biotechnology through a share swap, valuing Yiteng at $677 million and Jiahe at $197 million, resulting in Yiteng shareholders holding 77.43% and Jiahe shareholders 22.57% of the new entity [3]. - The new company will be named Yiteng Jiahe Pharmaceutical Group Limited, reflecting the merger of the two entities [2]. Group 2: Industry Context - The merger is seen as a "self-rescue" move for Jiahe Biotechnology, which has struggled with slow clinical progress and regulatory approvals, while Yiteng has faced challenges in its IPO attempts [4][6]. - The combination aims to leverage Jiahe's research capabilities and Yiteng's commercialization strengths, potentially creating a synergistic effect that enhances market competitiveness [7][9]. Group 3: Future Prospects - The merger is expected to accelerate the commercialization of Jiahe's product, GB491, and optimize its multi-specific antibody technology platform, while also establishing necessary commercial and regulatory capabilities [7][8]. - The transaction is viewed as a signal to the market regarding the value of mergers and acquisitions in the biotech sector, particularly for companies lacking stable cash flows [9].

港股18A首例反向收购有了新进展！ 近日，嘉和生物-B（06998.HK）提交的新上市申请通过港交所聆讯。根据上市申请书，亿腾医药通过 换股方式反向收购嘉和生物，合并后公司将更名为亿腾嘉和医药集团有限公司（以下简称"亿腾嘉 和"）。 这意味着，港股首单18A未盈利生物科技公司反向并购案例收官在即。根据嘉和生物披露的预期时间 表，两家公司合并完成以及公司更名的生效日期预计为12月30日。 双向困局下的自救 反向收购是指非上市公司股东通过收购壳公司（上市公司）股份实现控制，再通过壳公司反向收购非上 市公司资产，使后者成为子公司以实现间接上市。在A股中，这一操作通常称为"借壳上市"。 2024年10月，嘉和生物发布公告称，公司与亿腾医药订立合并协议。根据协议，亿腾医药以6.77亿美元 估值与嘉和生物1.97亿美元估值实施换股合并，合并后的新公司中，原亿腾医药股东占比77.43%，原嘉 和生物股东占比22.57%，亿腾医药实际控制人也将成为亿腾嘉和的控股股东。 在嘉和生物披露的信息中，这样介绍亿腾医药：通过向跨国医药公司收购品牌药物资产，以及从全球生 物制药公司授权引进创新专利药物的开发及商业化权利，目前已成功完成多 ...

Core Viewpoint - The reverse acquisition of Jiahe Biotech by Yiteng Pharmaceutical marks a significant development in the Hong Kong stock market, being the first case of an unprofitable biotech company under the 18A rule completing a reverse merger [1][3]. Group 1: Reverse Acquisition Details - Jiahe Biotech submitted a new listing application that has passed the Hong Kong Stock Exchange hearing, indicating the merger is nearing completion [1]. - The merger involves a share swap where Yiteng Pharmaceutical is valued at $677 million and Jiahe Biotech at $197 million, resulting in Yiteng shareholders holding 77.43% and Jiahe shareholders 22.57% of the new entity [3]. - The expected completion date for the merger and name change to Yiteng Jiahe Pharmaceutical Group Limited is December 30 [1]. Group 2: Company Background and Market Context - Jiahe Biotech has faced challenges with its clinical pipeline, which has been slow, and its products have not yet received domestic approval, leading to skepticism about its ability to recover independently [4]. - Yiteng Pharmaceutical has attempted to go public multiple times but has been unsuccessful, and it is perceived more as a contract sales organization rather than a company with strong self-research capabilities [5][6]. - The merger is viewed as a "self-rescue" effort for both companies, allowing Jiahe to leverage Yiteng's commercialization capabilities while Yiteng gains access to Jiahe's research pipeline [7]. Group 3: Strategic Implications - The merger is expected to create a synergistic effect, enhancing the market competitiveness of the combined entity by integrating research-driven and product commercialization capabilities [8][9]. - Jiahe Biotech aims to accelerate the commercialization of its product GB491 and optimize its multi-specific antibody technology platform through this merger [9][10]. - The transaction is seen as a potential signal for the market, indicating that the Hong Kong Stock Exchange may be more focused on the real value changes brought by mergers rather than just the shell value of companies [12].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公告所提述的本公司證券的邀請或要約。 GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業（開曼）控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6998） (4)有關股東人員留任計劃的特別交易； (5)建議更改公司名稱； (6)建議增加本公司法定股本；及 (7)建議採納一次性購股權計劃 寄發通函 茲提述嘉和生物藥業（開曼）控股有限公司（「本公司」）(i)日期為2024年10月7日的 公告（「第一份公告」），內容有關（其中包括）建議合併、新上市申請、清洗豁免、 股東人員留任計劃、建議更改公司名稱、建議增加本公司法定股本及建議採納一 次性購股權計劃（統稱「交易」）；(ii)日期為2024年10月28日及2025年6月26日的 公告，內容有關延遲寄發通函；(iii)日期為2024年11月26日的公告，內容有關委 任獨立財務顧問； ...

GENOR BIOPHARMA HOLDINGS LIMITED 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公告所提述的本公司證券的邀請或要約。 嘉和生物藥業（開曼）控股有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本 公司擬訂於2025年12月22日（星期一）舉行股東特別大會（「股東特別大會」）。為 釐定出席股東特別大會並於會上投票之權利，本公司將於2025年12月18日（星期 四）至2025年12月22日（星期一）（包括首尾兩日）暫停辦理股份過戶登記手續， 期間概不會辦理任何股份過戶登記。股東特別大會之記錄日期為2025年12月22日 （星期一）。為符合資格出席股東特別大會並於會上投票，所有股份過戶文件連同 有關股票須不遲於2025年12月17日（星期三）下午四時三十分送交回本公司之香 港股份過戶登記處香港中央證券登記有限公司，地址為香港灣仔皇后大道東183 號合和中心17樓1712-1716 ...